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Abstract
Background—The transcription factor TCF21 is involved in mesenchymal-to-epithelial
differentiation and was shown to be aberrantly hypermethylated in lung and head and neck
cancers. Because of its reported high frequency of hypermethylation in lung cancer, we sought to
characterize the stages and types of non-small cell lung cancer (NSCLC) that are hypermethylated
and to define the frequency of hypermethylation and associated “second hits”.
Methods—We determined TCF21 promoter hypermethylation in 105 NSCLC including various
stages and histologies in smokers and nonsmokers. Additionally, we examined TCF21 loss-of-
heterozygosity and mutational status. We also assayed 22 cancer cell lines from varied tissue
origins. We validated and expanded our NSCLC results by examining TCF21
immunohistochemical expression on a tissue microarray containing 300 NSCLC cases.
Results—Overall, 81% of NSCLC samples showed TCF21 promoter hypermethylation and 84%
showed decreased TCF21 protein expression. Multivariate analysis showed that TCF21
expression, although below normal in both histologies, was lower in adenocarcinoma than
squamous cell carcinoma, and was not independently correlated with gender, smoking and EGFR
mutation status, or clinical outcome. Cell lines from other cancer types also showed frequent
TCF21 promoter hypermethylation.
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Conclusions—Hypermethylation and decreased expression of TCF21 were tumor-specific and
very frequent in all NSCLC, even early-stage disease, thus making TCF21 a potential candidate
methylation biomarker for early-stage NSCLC screening. TCF21 hypermethylation in a variety of
tumor cell lines suggests it may also be a valuable methylation biomarker in other tumor types.
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Introduction
Lung cancer is the number one cause of cancer mortality worldwide, and kills more people
than breast, colon, and prostate cancer combined.1 Unlike these other common cancers,
however, there is no effective screening strategy to detect early-stage lung cancer at a time
when surgery may be curative. The need for such a strategy is obvious, and many attempts
to detect lung cancer early have so far failed to show clinical benefit.2-4 These include
screening CT scans, sputum cytology, screening chest X-rays, serum markers.
Recently, promoter hypermethylation has been recognized as an important mechanism by
which genes regulating cellular proliferation are silenced during cancer development5, 6
Promoter hypermethylation involves DNA methylation of CpG islands in or near the
promoter region of certain genes, rendering them transcriptionally silent. This
downregulation of gene expression of important cellular growth control genes has been
shown to be important for cancer progression and outcome, with poorer outcomes associated
with promoter hypermethylation of such important genes as RASSF1A, RARB, and HIF1.7-9
TCF21 is a recently recognized target of aberrant promoter hypermethylation in cancer,
discovered in a genomic screen for regions of DNA that are hypermethylated in cancer.10 It
was reported to be frequently hypermethylated in head and neck and lung cancer, and
restoration of TCF21 expression inhibited tumor growth, both in a lung cancer cell line and
in a mouse xenograft model. TCF21 is widely expressed; its normal function is to promote
mesenchymal transition into epithelial cells.11 Reversal of this process, known as the
epithelial-to-mesenchymal transition (EMT), has been implicated in tumor invasion and
metastasis;12, 13 Therefore, silencing of TCF21 may be a mechanism for tumor cells to gain
these aggressive characteristics during the course of tumor progression. Given that TCF21
was reported to be frequently hypermethylated and silenced in NSCLC, as well as its
plausible biologic role in tumor progression, we sought to more precisely define the
frequency of TCF21 promoter hypermethylation in NSCLC. We were especially interested
in defining its frequency among different cancer stages and histologic subtypes. Here, we
show that TCF21 is very frequently hypermethylated in a variety of NSCLC, and that
protein expression of TCF21 is also very frequently reduced, either of which could be used
for screening and/or diagnostic purposes as a biomarker of early disease.
Materials and Methods
Frozen Tumor Specimens, Cell Lines, and DNA Extraction
Patient NSCLC specimens were obtained from surgical specimens at both the University of
Texas M. D. Anderson Cancer Center (42 matched tumor/normal samples, 7 unpaired tumor
samples) as well as from the University of North Carolina Lineberger Comprehensive
Cancer Center tumor bank of surgical specimens (56 unpaired tumor samples). In both
institutions, informed consent was obtained prior to surgery for the use of specimens as part
of an IRB-approved protocol, in accord with the Helsinki Declaration. Tissue was snap-
frozen and used for later DNA extraction. Genomic DNA was extracted from the DNA-
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protein phase of TriZol-extracted tissues according to the manufacturer's suggestions
(Invitrogen). DNA was extracted using the PureGene kit (Gentra) on cell pellets from four
HNSCC cell lines (SCC-4, SCC-9, SCC-15 and SCC-25), five lung cancer cell lines
(H1395, H520, H2170, SK-MES-1 and SW-900), one breast cancer cell line (MCF7), one
cervical cancer cell line (HeLa), two brain cancer cell lines (SK-N-AS and M059K), one
uterine cancer cell line (AN3CA), one sarcoma cell line (HT1080), one kidney cancer cell
line (HEK293), and six colon cancer cell lines (LoVo, SW48, HCT-15, DLD-1, COLO
320DM and RKO) according to the manufacturer's suggestions. All cell lines are available
from ATCC (Manassas, VA). Four normal pools, each comprised of DNA from peripheral
blood mononuclear cells (PBMCs) of six individuals were generated representing different
genders and ages (females ≤40 yrs of age, females age >40 yrs, males ≤40 yrs and males
≥40 yrs).
TCF21 Promoter Methylation
PCR and sequencing primers were designed using the PSQ Assay Design software (Qiagen).
PCR was performed in a 25 μl reactions containing Qiagen HotStart Taq master mix
(Qiagen) using 1 μl bisulfate-converted DNA (about 10 ng/μl). Bisulfite conversion of
genomic DNA was performed as previously reported.14 Briefly, 0.5-1.0 μg of genomic DNA
was treated using the EZ-96 DNA Methylation Gold Kit (Zymo Research), including DNA
sulfonation, deamination, desalting, desulfonation and recovery. Bisulfite-treated DNA was
stored at −80°C until use. To reduce the cost per assay, an amplification protocol was
developed using a biotinylated universal primer approach.14 Final primer concentrations
were 10 nM of the reverse primer tailed with the universal primer (5′-
GACGGGACACCGCTGATCGTTTACCAAAAAAAACCCCCTAA-3′), 100 nM of the
untailed forward primer (5′-GGTAGGGTGGTTTTGAGTT-3′), and 90 nM of the universal
biotinylated primer (5′-GGGACACCGCTGATCGTTTA-3′) in each reaction. The universal
primer sequence is underlined. The predicted amplicon size was 153 bp. Amplification was
carried out as follows: denaturation at 95°C for 5 min, followed by 50 cycles at 95°C for 30
sec, 51°C for 1 min, 72°C for 45 sec, and a final extension at 72°C for 7 min.
Following PCR amplification, Pyrosequencing was performed on a PSQ96HS system
(Qiagen) according to the manufacturer's protocol including the use of single strand binding
protein (PyroGold reagents). The Pyrosequencing primer was (5′-
TTGAGTTTGGAGAAGG-3′). The results were analyzed using Q-CpG software (Qiagen),
which calculates the methylation percentage (mC/(mC+C)) for each CpG site, allowing
quantitative comparisons. The methylation index (MI) was calculated as the average value
of mC/(mC+C) for all nine of the interrogated CpG sites in the assay. Genomic DNA treated
with M.SssI (New England Biolabs) was used as a universally methylated positive control;
the same untreated genomic DNA amplified by whole genome amplification (GenomiPhi,
GE Healthcare) was used as a universally unmethylated negative control.
Decitabine Treatment and Quantitative Real-Time RT-PCR
Three colon cancer cell lines (DLD-1, HCT-15 and RKO) with high levels (>85%) of
TCF21 promoter hypermethylation were plated at a density of 500,000 cells/T75 flask.
DLD-1 and HCT-15 cells were grown in RPMI-1640 supplemented with 10% FBS and 1%
penicillin/streptomycin, RKO cells in EMEM supplemented with 10% FBS and 1%
penicillin/streptomycin. Drug treatment with 1 μM decitabine (Sigma-Aldrich, St. Louis,
MO) was started 3 hrs after seeding. Culture medium and drug were changed daily for
treated and untreated cells. Cultures were grown for a minimum of four days until 80%
confluency. Total cellular RNA was isolated using TRIZol reagent (Invitrogen). Input RNA
(1 μg) was reverse-transcribed using the iScript cDNA Synthesis Kit (Bio-Rad, Hercules,
CA). TCF21 expression was assessed by TaqMan qRT-PCR using assays Hs00162646_m1
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and Hs01546814_m1 (Applied Biosystems, Foster City, CA, USA) covering exon 1-2 and
exon 2-3, respectively. qRT-PCR was carried out as follows in 20-μl final reaction volume
using 55 ng of RNA-equivalents as cDNA input: initial denaturation at 95°C for 8.5 min,
followed by 45 cycles at 95°C for 15 sec and 60°C for 1 min according to the manufacturer's
suggestions. GUSB (Hs99999908_m1) was used as endogenous housekeeping gene control
for normalization. Each assay was performed in triplicate. Relative expression levels were
calculated using the △△Ct method and scaled.
LOH and Mutation Detection
Primers were designed for detection of four microsatellites within and flanking TCF21.
Primer sequences are shown in Table 1. All forward primers were 5′-tailed with 5′-
GACGGGACACCGCTGATCGTTTA-3′ and all reverse primers were 5′-tailed with 5′-
GTTTCTT-3′. A universal primer with the sequence 5′-GGGACACCGCTGATCGTTTA-3′
end-labeled with either FAM, HEX, or NED was used in all microsatellite amplifications.
PCR conditions for the three primer reactions were as described above for amplification
using the universal biotinylated primer. Amplification products were pooled as appropriate
and analyzed by capillary electrophoresis on an ABI 3100 Genetic Analyzer (Applied
Biosystems).
The coding region of TCF21 (exons 1 and 2) was sequenced in both directions in four
fragments. In all, 45 lung cancer samples showing zero or one hit were sequenced. Samples
which had already been scored as having two hits were not sequenced. Primer sequences are
shown in Table 1. All forward primers were 5′-tailed with M13 forward sequence 5-
TGTAAAACGACGGCCAGT-3′, and all reverse primers with M13 reverse 5′-
CAGGAAACAGCTATGACC-3′. After amplification, samples were treated with Exo-SAP
(Amersham), sequenced using Big Dye Terminator v3.1 (Applied Biosystems) under
standard conditions and products purified by ethanol precipitation, dehydrated in a vacuum
centrifuge, and resuspended in 20 μl formamide before capillary electrophoresis on an ABI
3100 Genetic Analyzer. Sequences were aligned and visualized using Sequencher software
(Gene Codes). Fragment 1 contained a polymorphic (CT)n simple tandem repeat of 8 to 12
units, which, when polymorphic, was used to confirm retention-of-heterozygosity identified
by the microsatellites.
Archival NSCLC Case Selection and Tissue Microarray Construction
We obtained archival, formalin-fixed and paraffin-embedded (FFPE) material from
surgically resected lung cancer specimens containing tumor and adjacent lung tissues from
the Lung Cancer Specialized Program of Research Excellence (SPORE) Tissue Bank at The
University of Texas M. D. Anderson Cancer Center, which was approved by the
Institutional Review Board. Tumor tissue specimens from 300 NSCLCs (191
adenocarcinomas, and 109 squamous cell carcinomas) were histologically examined,
classified using the 2004 World Health Organization (WHO) classification system,15 and
selected for tissue microarray (TMA) construction. After histologic examination, TMAs
were constructed using triplicate 1-mm diameter cores from each tumor. Detailed clinical
and pathological information, including demographic data, smoking history (never- and
ever-smokers) and status (never, former, and current smokers), pathologic TNM staging,16
overall survival, and time of recurrence, was available in most cases (Table 2). Patients who
had smoked at least 100 cigarettes in their lifetime were defined as smokers, and smokers
who quit smoking at least 12 months before lung cancer diagnosis were defined as former
smokers.
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Immunohistochemical Staining and Evaluation
An anti-human TCF21 antibody was used for immunostaining (ab32981, Abcam). FFPE
tissue histology sections (5-μm thick) were deparaffinized, hydrated, heated in a steamer for
10 min with 10 mM sodium citrate (pH 6.0) for antigen retrieval. Peroxide blocking was
performed with 3% H2O2 in methanol at room temperature for 15 min, followed by 10%
bovine serum albumin in TBS-t for 30 min. Slides were incubated with primary antibody at
1:200 dilution for 65 minutes at room temperature. After washing with TBS-t, incubation
with biotin-labelled secondary antibody for 30 min followed. Finally, samples were
incubated with a 1:40 solution of streptavidin-peroxidase for 30 min. The staining was then
developed with 0.05% 3′,3-diaminobenzidine tetrahydrochloride prepared in 0.05 mol/l Tris
buffer at pH 7.6 containing 0.024% H2O2 and counterstained with hematoxylin. FFPE lung
tissues having normal bronchial epithelia were used as positive control. For a negative
control, we used the same specimens used for the positive controls, replacing the primary
antibody with PBS.
TCF21 immunostaining was detected in the cytoplasm of epithelial and tumor cells.
Immunohistochemical expression was quantified by microscope observation by two
pathologists (M.S. and I.W.) using a four-value intensity score (0, 1+, 2+ and 3+) and the
percentage of the reactivity extent. A final score was obtained by multiplying both intensity
and extension values (range 0-300), and four levels of expression were arbitrarily calculated
based on that score: (a) negative (score 0-9); (b) low (score 10-100); (c) intermediate (score
100 to 199); and (d) and high (score 200-300). Levels and scores were used for analysis.
EGFR Mutation Analysis
Exons 18 through 21 of EGFR were PCR amplified using intron-based primers as previously
described.17, 18 From microdissected FFPE cells, ∼200 cells were used for each PCR
amplification. All PCR products were directly sequenced using the PRISM dye-terminator
cycle sequencing method (Applied Biosystems). All sequence variants were confirmed by
independent PCR amplifications from at least two independent microdissections and DNA
extraction, and sequenced in both directions, as previously reported.
Statistical Analysis
The clinical and pathological data were summarized using descriptive statistics and
frequency tabulations. Wilcoxon rank-sum and Kruskal-Wallis tests were used to compare
biomarker expression among different prognostic factor levels. The generalized linear model
was used to assess the effect of prognostic factors on TCF21 expression in the multivariable
setting. Fisher's exact test was used to compare the association between categorical
variables. We examined the association between overall survival (OS) and recurrence-free
survival (RFS) rates and TCF21 expression in NSCLC patients with stage I or II disease,
who had not undergone adjuvant chemotherapy. OS was defined as the time from surgery to
death or the end of the study; RFS was defined as the time from surgery to recurrence or the
end of the study. Univariate and multivariate Cox proportional hazards models were used to
assess the effects of TCF21 protein expression on survivals. Two-sided p-values<0.05 were
considered statistically significant. All analyses were conducted using SAS (v 9.1, Cary,
NC) and S-plus (v 8.0, Seattle, WA) software.
Results
TCF21 is Highly Methylated in Nearly All Cancer Cell Lines
To characterize TCF21 methylation levels in normal and malignant states, we examined
various cancer cell lines from a spectrum of tissue types (brain, breast, cervix, colon,
connective tissue, head and neck, kidney, lung, and uterus). We also assayed TCF21
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methylation in normal PBMCs from younger and older individuals of both sexes, since
methylation levels can be influenced by age and/or sex. Universally methylated control
DNA and genetically matched unmethylated control DNA defined the boundaries of
detection of our assay (3-93% methylation). Using Pyrosequencing-based Methylation
Analysis (PMA) we analyzed TCF21 methylation by averaging methylation levels of nine
promoter CpG sites. All but one cell line (SK-N-AS, a neuroblastoma cell line, 38%) was
highly methylated, with levels at or approaching the upper limit of detection (Fig. 1).
Normal PBMCs were essentially identical regardless of age or gender, and demonstrated
moderate levels of baseline methylation at ∼20%.
TCF21 is Hypermethylated in >80% of NSCLC
To define the threshold for hypermethylation positivity, we began our analysis using
genetically matched NSCLC and adjacent normal tissue pairs from the same patient. To
assess the baseline levels of TCF21 methylation in lung tissue, we examined both normal
adjacent tissue (NAT) from the tumor/normal (T/N) pairs (n=42) comparing them to PBMC.
Average methylation levels in NAT were 21.5% (SD=4.6; n=42), and in the normal PBMC
20.1%. Average TCF21 methylation levels in T samples were 41.3% (SD=11.6; n=42) (Fig.
2A). The difference between the average methylation levels in N and T tissues was highly
significant (p-value<1×10-13).
Using a threshold of 30% methylation, we found that 37 of 42 tumors (88%) were
hypermethylated, while 41 of 42 matched normal samples (98%) were not. Using this cutoff
to define hypermethylation, we then assayed second set of 63 unpaired NSCLC samples.
This second set of tumors contained a small number of large cell histologic subtypes, and
some mixed histologic types (mostly adeno-squamous). We found that 48 (76%) of them
were hypermethylated (Fig. 2B). Overall, the average methylation levels of all the tumor
samples combined was 39.2% (SD=11.7; n=105). Using the threshold of 30% methylation,
the overall frequency of hypermethylation in NSCLC was 81% (85/105).
Reactivation of TCF21 Expression by Demethylating Agent
To show that TCF21 promoter hypermethylation correlates with transcriptional silencing of
the gene, we treated three colorectal cancer cell lines with high methylation levels (>85%)
with the demethylating drug decitabine. We performed quantitative TaqMan mRNA real-
time PCR to determine relative TCF21 expression levels with and without treatment. For all
three cell lines culturing in the presence of the demethylating agent led to reactivation of
TCF21 expression at the mRNA level as assayed by two distinct quantitative real-time PCR
assays (Fig. 3).
Reduced Expression of TCF21 Protein in NSCLC
To determine whether TCF21 promoter hypermethylation also resulted in decreased TCF21
protein expression, we used a NSCLC TMA containing tumor samples from 300 patients.
The microarray was stained with a TCF21 antibody, and protein levels were scored as none,
low, intermediate, or high (Fig. 3A). While normal adjacent lung tissue stained strongly for
TCF21, 253 of 300 (84%) NSCLC samples showed reduced (either low or none) staining
(Fig. 3B).
Similar frequencies of TCF21 hypermethylation and decreased protein expression suggested
that hypermethylation leads to reduced protein levels, which would be consistent with
previously reported decreased mRNA levels resulting from TCF21 promoter
hypermethylation.10 Because our TMA included only 9 overlapping samples between the
TMA and TCF21 methylation sets, we assembled a smaller TMA with 31 samples
overlapping (Table 3). Interestingly, TCF21 hypermethylation and reduced TCF21 protein
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expression were sometimes discordant (Table 3), suggesting that mechanisms other than
hypermethylation could result in decreased protein expression.
TCF21 Loss-of-Heterozygosity and Sequence Analysis
Because some NSCLC samples showed loss of TCF21 protein expression without
hypermethylation and the average levels of TCF21 hypermethylation were ∼40%, which
might not be expected to completely abolish protein expression, we examined potential
“second hits” at the TCF21 locus (Table 3). First, we examined loss-of-heterozygosity
(LOH) in 33 of the paired samples, using four microsatellite markers spanning the TCF21
locus and closely flanking region. LOH was seen in 14 (42%) of these samples, with no
significant differences comparing samples with and without hypermethylation (p-
value=0.172). In addition to LOH, we sequenced the TCF21 coding region in 45 lung cancer
samples that showed either zero or one hit by methylation or LOH analysis. Samples with
both hypermethylation and LOH were not sequenced. No TCF21 coding mutations were
found.
Reduced TCF21 Protein Expression is Widespread and Independent of Stage and Other
Clinical Features, but Correlated with Histology
To determine whether TCF21 expression was correlated with clinical features such as
gender, race, stage, smoking status, histology, or prognosis, we performed univariate
analysis (Table 2). Histology and TCF21 expression showed significant correlation (p-
value=0.003), as did smoking status (p-value=0.048) and gender (p-value=0.021). In a
multivariate analysis with histology, gender, and smoking status, only histology was
statistically significantly (p-value = 0.007) associated with TCF21 levels, while smoking
history and gender were not independently associated. Cox proportional hazards analysis
was performed to assess association between TCF21 and overall survival and recurrence-
free survival, but neither association was significant, in either a multivariate model or a
univariate model (data not shown).
Given previously reported associations between smoking, gender, and histology with EGFR
status,19 we then analyzed the 202 patient subset for which EGFR status was known, for
associations with TCF21 expression. When only adenocarcinomas were considered (n =
172), EGFR status was not associated with TCF21 expression level (p-value = 0.138), nor
was EGFR status associated with TCF21 expression level in a univariate analysis with all
202 patients (p-value = 0.241). Therefore, the only significant correlation (p-value = 0.007)
is that adenocarcinomas have lower levels of TCF21 expression than SCCs, although all
histologies have significantly lower TCF21 levels than those in normal tissue.
Discussion
TCF21 Has the Highest Frequency of Promoter Hypermethylation in NSCLC of Any Gene
Known to Date
Many genes have been reported to be hypermethylated in NSCLC.20-24 However, the
frequency of these events has not been high enough in all NSCLC subtypes for utilization as
a screening tool, requiring combinations of genes to approach a sensitivity high enough for a
screening test. Despite numerous reports of hypermethylated genes in NSCLC, identified by
a variety of approaches, none has a reported frequency of hypermethylation as high as
TCF21, except one that also examined TCF21 itself, and a recent publication limited to only
the SCC subtype of NSCLC.20-23 This study was specifically focused on TCF21 in NSCLC
and the susceptibility locus at 6q23-q25. Among 43 genes selected in the region, TCF21 had
the highest rates of cancer-specific hypermethylation (81%),23 exactly matching our rates of
TCF21 hypermethylation.
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The high rates (80-85%) of TCF21 promoter hypermethylation and decreased protein
expression are high enough for TCF21 to be considered for development as a screening
biomarker, either by increased methylation or decreased protein levels. The sensitivity of
TCF21 hypermethylation/decreased TCF21 protein expression compares favorably with that
of prostate-specific antigen (PSA), the current screening biomarker for prostate cancer,
which has been shown to be <4 (i.e., in the normal range) in 15% of men with prostate
cancer, a sensitivity of 85%.25 Of course, one of the main difficulties in lung cancer
screening remains in the acquisition of relevant tissue (in this case early lung tumors), but
detection of TCF21 hypermethylation has been reported in biopsies and sputum samples,
which is promising.26 If its sensitivity in sputum/bronchial brushings were not high enough
to be used alone, TCF21 could be used as part of a panel of screening biomarkers.
Detection of TCF21 Hypermethylation by Highly Quantitative Method
One significant advantage of methylation detection by Pyrosequencing-based Methylation
Analysis (PMA) following bisulfite conversion is that quantitative levels can be measured
across multiple sites, rather than the more qualitative output obtained with methylation-
specific PCR (MS-PCR) or other qualitative or semiquantitative methods (e.g., COBRA).
PMA enabled us to reliably detect a difference between the 20% average methylation in N
tissue, and 40% average methylation in T tissue. This difference would likely not have been
detected with less quantitative methylation detection strategies. It is possible that other genes
known to be hypermethylated in NSCLC may prove to be more sensitive and/or specific, if
more quantitative methods such as Pyrosequencing are routinely applied. The 40%
methylation levels in NSCLC tissue raises the question of whether only one of the two
TCF21 alleles is silenced by hypermethylation, or whether 40% of cells have both alleles
silenced, either of which could produce the observed result. It is interesting that
hypermethylation of 40% of alleles is frequently associated with completely absent TCF21
protein expression, suggesting either that the second allele is silenced by a different
mechanism than hypermethylation, or that there is a threshold level of gene expression
necessary to produce detectable TCF21 protein levels.
Reduction of TCF21 Protein Levels Similar to TCF21 Hypermethylation Rates
In addition to TCF21 hypermethylation, we also examined the downstream effect of this
hypermethylation by examining protein expression directly. In both cases we found TCF21
hypermethylation/decreased TCF21 protein levels at similar rates--81% and 84%,
respectively. Given that decreased mRNA expression of TCF21 has been shown to result
from promoter hypermethylation,10 the similar rates of hypermethylation and decreased
protein expression are consistent with the notion that decreased mRNA expression results in
decreased protein expression. However, since there were cases with low/absent protein
expression despite normal TCF21 methylation levels, other regulatory mechanisms likely
are in effect. LOH occurs at a rate of 42%. Since LOH occurs in at least a few cases without
TCF21 hypermethylation, this implies inactivation of TCF21 in other ways. Since we did
not detect any coding mutations, these could be promoter or other regulatory region DNA
mutations. Alternatively, dysregulation by micro-RNAs could be a factor. Interestingly, the
sole predicted regulator of TCF21 is miR-92a,27 which is overexpressed in a variety of
cancers.28, 29
TCF21 is an Excellent Candidate Biomarker for Early Lung Cancer Detection
Several characteristics of TCF21 make it an attractive target for screening efforts in NSCLC.
First, it is hypermethylated at similar frequencies in all histologic subtypes of NSCLC
examined, including early- and late-stage cancers. Second, it has a higher frequency of
hypermethylation than any gene published to date in NSCLC, without subdivision by
histologic subtype.10, 20-23 This high sensitivity is combined with a high specificity as well.
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We detected a false-positive rate of only 1 in 42 samples with NAT, for a specificity of 98%.
In other reported control tissues, such as PBMCs and human bronchial epithelial cells
(HBECs) from smokers, there were no false-positives (n=20 in each case).23 The high
specificity in normal adjacent tissue is especially noteworthy in that there appears to be no
evidence for a “field-effect”, which can complicate screening in smokers who often have
cancers arising in a field of premalignant lesions, leading to false-positive screening results.
Instead, the very low prevalence of TCF21 hypermethylation in NAT that we report
suggests that TCF21 hypermethylation is restricted to cancerous tissue only.
In summary, we have established that TCF21 hypermethylation and reduced TCF21 protein
are ubiquitous in NSCLC, occurring in 80-85% of tumors across a wide variety of stages,
histologies, and other clinical characteristics. Given the high rate of increased methylation
and decreased protein expression, combined with their lack in normal adjacent tissue, we
propose that TCF21 is an excellent candidate biomarker for further development as a lung
cancer screening tool.
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Methylation levels of individual cancer cell lines, normal PBMCs, and positive and negative
methylation controls. TCF21 promoter methylation levels are shown for 22 cancer cell lines,
four pools of PBMCs of different sex (male, female) and age (≤40, >40 yrs). Control
samples, fully methylated by treatment with SssI methylase or fully unmethylated by whole
genome amplification, are also shown.
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Methylation levels and percent of tumors with methylation levels >30% threshold. (A)
TCF21 promoter methylation levels are shown in a box and whisker plot for 42 normal
adjacent lung tissues, 42 NSCLC tumors, 63 additional NSCLC tumors, all 105 NSCLC
tumors combined, and 24 HNSCC tumors. (B) Bar graph representing the number of
NSCLC and HNSCC tumors exceeding the 30% threshold for hypermethylation.
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Reactivation of TCF21 expression by demethylating agent decitabine. Quantitative TaqMan
mRNA real-time PCR results interrogating exon junctions of exons 1/2 and exons 2/3 in
three colorectal cancer cell lines with high methylation levels (>85%) with and without
decitabine treatment are shown.
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TCF21 protein expression. (A) TCF21 immunohistochemical expression in lung cancer.
NSCLC samples were stained with an anti-TCF21 antibody and scored as none, low,
medium, or high. Representative examples of SCC and adenocarcinoma samples with high
TCF21 expression (left) and no TCF21 staining (right) are shown. (B) Frequency of TCF21
expression in NSCLC on the TMA (300 patients). The percentage of samples in each
expression category is shown. Reduced expression was defined as “none” or “low”.
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